Welcome to our dedicated page for TFF Pharmaceuticals news (Ticker: TFFP), a resource for investors and traders seeking the latest updates and insights on TFF Pharmaceuticals stock.
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative drug products utilizing their patented Thin Film Freezing (TFF) technology. This groundbreaking technology allows for the transformation of both existing compounds and new chemical entities into dry powder formulations. The TFF platform provides numerous advantages, including high absorption and yield, uniform particle size, and a gentle process that preserves the integrity of complex therapeutic components.
Core Business and Products
TFF Pharmaceuticals has two lead drug candidates currently under clinical evaluation: Voriconazole Inhalation Powder (TFF VORI) and Tacrolimus Inhalation Powder (TFF TAC). These inhaled dry powder drugs are designed to treat lung disorders and organ transplant rejection, respectively.
Recent Achievements and Projects
Recently, TFF Pharmaceuticals announced positive data from their ongoing Phase 2 study of TFF TAC, which is being developed to prevent organ rejection in lung transplant recipients. The study indicates that TFF TAC provides sufficient immunosuppression to prevent rejection at significantly reduced doses compared to oral tacrolimus, potentially reducing the risk of kidney toxicity.
Financial Condition and Partnerships
As of the first quarter of 2024, TFF Pharmaceuticals has secured additional financing to continue advancing their TFF TAC program toward registrational testing. The company is actively collaborating with large pharmaceutical companies, academic institutions, and government partners to expand their pipeline and revolutionize healthcare globally.
Technology and Patents
The TFF technology platform is protected by over 170 patents issued or pending in the U.S. and internationally. This versatile platform can convert vaccines, small and large molecules, and biologics into elegant dry powders, making them ideal for inhalation or topical delivery.
The company’s proprietary TFF process allows for the direct delivery of therapies to target organs such as the lungs, which can improve bioavailability, reduce dosages, and minimize side effects. Laboratory data suggest that the aerodynamic properties of TFF powders can deliver as much as 75% of the dose to the deep lung.
Conclusion
TFF Pharmaceuticals is at the forefront of transforming biopharmaceutical delivery methods with its innovative TFF technology. By developing dry powder formulations that offer enhanced efficacy, safety, and stability, the company is poised to make significant impacts in the treatment of lung disorders and beyond.
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) announced successful treatment of a second patient with Voriconazole Inhalation Powder (TFF VORI) through a compassionate use program in Melbourne, Australia. This follows the presentation of positive results from the first patient at the 15th Annual International Congress on Lung Transplantation. TFF VORI, a dry powder formulation of voriconazole, aims to treat Invasive Pulmonary Aspergillosis (IPA). After six weeks of therapy, the second patient showed stabilized lung function and negative cultures for aspergillus, supporting TFF VORI's safety and efficacy advantages.
TFF Pharmaceuticals, Inc. (TFFP) announced updates on its clinical programs for Voriconazole Inhaled Powder (TFF VORI) and Tacrolimus Inhaled Powder (TFF TAC) on November 1, 2022. Preliminary data from Phase 2 studies is expected in Q1 2023 for TFF VORI and Q2 2023 for TFF TAC, but timelines have been impacted by staffing shortages and supply chain delays. TFF's CEO emphasized the ongoing commitment to overcoming these challenges while highlighting the potential benefits of TFF technology for targeted drug delivery.
TFF Pharmaceuticals (NASDAQ: TFFP) announced two poster presentations featuring its patented Thin Film Freezing (TFF) technology at the AAPS PharmSci 360 Meeting in Boston, scheduled for October 16-19, 2022. The presentations highlight the use of TFF in developing dry powder inhaled formulations of monoclonal antibodies, including anti-SARS-CoV-2 and anti-PD-1 antibodies. Additionally, the company will discuss applications of artificial intelligence in optimizing aerosol performance. TFF's technology aims to enhance the bioavailability and efficiency of drug delivery.
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) announced participation of President and CEO Glenn Mattes at the Roth Inaugural Healthcare Opportunities Conference on October 6, 2022, in New York City. The company will also hold one-on-one meetings during the event. TFF Pharmaceuticals focuses on innovating drug delivery through its patented Thin Film Freezing (TFF) technology, which can convert various compounds into dry powder formulations with enhanced bioavailability and safety. The technology aims to revolutionize drug administration across multiple routes.
TFF Pharmaceuticals (TFFP) announced that two of its research abstracts, focusing on Thin Film Freezing (TFF) technology, have been accepted for presentation at the AAPS PharmSci 360 Meeting in October 2022. The studies emphasize TFF’s potential for producing stable dry powder inhaled formulations of monoclonal antibodies and utilizing machine learning to predict aerosol performance. These advancements highlight TFF's commitment to enhancing drug delivery systems and expanding its collaborations in biologics.
TFF Pharmaceuticals reported promising results from the compassionate use of its inhaled Voriconazole Powder (TFF VORI) for a lung transplant patient intolerant to oral therapy. Presented by Dr. Bradley Gardiner at the 15th International Congress on Lung Transplantation, TFF VORI has been successfully administered since February 2022, stabilizing the patient’s lung function without the toxicities associated with oral voriconazole. The treatment underscores the potential safety and efficacy of TFF VORI, with expectations of further validation in ongoing Phase 2 studies.
TFF Pharmaceuticals (NASDAQ: TFFP) announced that President and CEO Glenn Mattes will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, at the Lotte New York Palace. Mattes will present on September 12 at 5:00 PM EST and will engage in one-on-one meetings throughout the event. The conference will highlight TFF's Thin Film Freezing (TFF) technology, which transforms drugs into more effective dry powder formulations. A webcast of the presentation will be available for 90 days following the event.
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) provided a Q2 2022 update, reporting cash reserves of $20.9 million. R&D and G&A expenses rose to $5.1 million and $3.7 million respectively, contributing to a net loss of $8.7 million. The company is advancing its Phase 2 studies for Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder, highlighting significant industry partnerships with three top 20 pharma companies. A new R&D facility in Austin, Texas, enhances their operational capacity. Ongoing feasibility studies show promise for next-generation vaccines using Thin Film Freezing technology.
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) announced a conference call scheduled for August 11, 2022, at 4:30 PM ET, to discuss its second quarter financial results and recent developments. The call will include a Q&A session for investors. The company is known for its innovative Thin Film Freezing (TFF) technology, which transforms drugs into dry powders for enhanced delivery and efficacy. Despite ongoing advancements, the company faces challenges, including the lack of FDA approvals for its products and uncertainties surrounding clinical testing outcomes.
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) announced the lease of a new 3,500 square foot R&D facility in Austin, Texas, aimed at enhancing its internal pipeline and accommodating growing partnered projects. This expansion will increase manufacturing capabilities for its patented Thin Film Freezing technology, enabling larger-scale production and feasibility studies, particularly in biologics. The facility is expected to support ongoing clinical evaluations and strengthen collaborations with academic institutions. The new lab will be overseen by experienced staff and is designed to optimize resource use and preserve capital.
FAQ
What is the current stock price of TFF Pharmaceuticals (TFFP)?
What is the market cap of TFF Pharmaceuticals (TFFP)?
What is TFF Pharmaceuticals, Inc.?
What is Thin Film Freezing (TFF) technology?
What are the lead drug candidates of TFF Pharmaceuticals?
What recent achievements has TFF Pharmaceuticals made?
How does TFF technology benefit drug delivery?
How many patents protect TFF Pharmaceuticals' technology?
Who are TFF Pharmaceuticals' partners?
What financial condition is TFF Pharmaceuticals in?
Where can I find more information about TFF Pharmaceuticals?
What are the next steps for TFF Pharmaceuticals' clinical trials?
